Logo image of COYA

COYA THERAPEUTICS INC (COYA) Stock Fundamental Analysis

NASDAQ:COYA - Nasdaq - US22407B1089 - Common Stock - Currency: USD

6.88  +0.59 (+9.38%)

After market: 7.4999 +0.62 (+9.01%)

Fundamental Rating

3

Taking everything into account, COYA scores 3 out of 10 in our fundamental rating. COYA was compared to 572 industry peers in the Biotechnology industry. COYA has a great financial health rating, but its profitability evaluates not so good. COYA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

COYA had negative earnings in the past year.
COYA had a negative operating cash flow in the past year.
COYA Yearly Net Income VS EBIT VS OCF VS FCFCOYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

COYA has a better Return On Assets (-30.09%) than 67.36% of its industry peers.
Looking at the Return On Equity, with a value of -33.42%, COYA is in the better half of the industry, outperforming 75.74% of the companies in the same industry.
Industry RankSector Rank
ROA -30.09%
ROE -33.42%
ROIC N/A
ROA(3y)-89.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COYA Yearly ROA, ROE, ROICCOYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 100 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COYA Yearly Profit, Operating, Gross MarginsCOYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

8

2. Health

2.1 Basic Checks

COYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for COYA has been increased compared to 1 year ago.
COYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COYA Yearly Shares OutstandingCOYA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M
COYA Yearly Total Debt VS Total AssetsCOYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 18.34 indicates that COYA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 18.34, COYA belongs to the best of the industry, outperforming 93.89% of the companies in the same industry.
COYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.34
ROIC/WACCN/A
WACC10.48%
COYA Yearly LT Debt VS Equity VS FCFCOYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

COYA has a Current Ratio of 15.31. This indicates that COYA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of COYA (15.31) is better than 90.92% of its industry peers.
COYA has a Quick Ratio of 15.31. This indicates that COYA is financially healthy and has no problem in meeting its short term obligations.
COYA has a better Quick ratio (15.31) than 90.92% of its industry peers.
Industry RankSector Rank
Current Ratio 15.31
Quick Ratio 15.31
COYA Yearly Current Assets VS Current LiabilitesCOYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

COYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.21%, which is quite impressive.
EPS 1Y (TTM)43.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, COYA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.90% on average per year.
COYA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.91% yearly.
EPS Next Y-41.06%
EPS Next 2Y-29.68%
EPS Next 3Y-19.15%
EPS Next 5Y11.9%
Revenue Next Year-11.09%
Revenue Next 2Y17.86%
Revenue Next 3Y7.28%
Revenue Next 5Y43.91%

3.3 Evolution

COYA Yearly Revenue VS EstimatesCOYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
COYA Yearly EPS VS EstimatesCOYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year COYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COYA Price Earnings VS Forward Price EarningsCOYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COYA Per share dataCOYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

COYA's earnings are expected to decrease with -19.15% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.68%
EPS Next 3Y-19.15%

More info and screens

0

5. Dividend

5.1 Amount

COYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COYA THERAPEUTICS INC

NASDAQ:COYA (3/7/2025, 8:15:54 PM)

After market: 7.4999 +0.62 (+9.01%)

6.88

+0.59 (+9.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)03-26 2025-03-26/bmo
Inst Owners21.39%
Inst Owner Change-3.63%
Ins Owners1.4%
Ins Owner Change0.93%
Market Cap114.96M
Analysts83.64
Price Target15.81 (129.8%)
Short Float %1.77%
Short Ratio3.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.76%
Min EPS beat(2)-33.05%
Max EPS beat(2)38.58%
EPS beat(4)2
Avg EPS beat(4)-0.82%
Min EPS beat(4)-33.05%
Max EPS beat(4)38.58%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-56.95%
Min Revenue beat(2)-100%
Max Revenue beat(2)-13.89%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.8%
EPS NQ rev (1m)-3.25%
EPS NQ rev (3m)15.87%
EPS NY rev (1m)-2.42%
EPS NY rev (3m)2.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)0.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.03
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 3.59
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.57
BVpS1.92
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.09%
ROE -33.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-89.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.31
Quick Ratio 15.31
Altman-Z 18.34
F-Score6
WACC10.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
EPS Next Y-41.06%
EPS Next 2Y-29.68%
EPS Next 3Y-19.15%
EPS Next 5Y11.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-11.09%
Revenue Next 2Y17.86%
Revenue Next 3Y7.28%
Revenue Next 5Y43.91%
EBIT growth 1Y4.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-67.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.79%
OCF growth 3YN/A
OCF growth 5YN/A